Development of Biopharmaceuticals and Vaccines in the Region will be Better Between Panama and Brazil
This commitment aligns with Senacyt’s efforts to position Panama as a benchmark in biopharmaceutical research, development, and production.
Regarding President José Raúl Mulino’s official visit to Brazil, a joint declaration was issued with President Luiz Inácio Lula da Silva, in which they agreed to strengthen bilateral cooperation in science, technology, and innovation. Both countries commissioned the National Secretariat of Science, Technology and Innovation (Senacyt) and the Oswaldo Cruz Foundation (Fiocruz) of Brazil to explore strategic alliances aimed at scientific and technological development.
The agreement, contained in the presidential declaration, highlights the importance of boosting regional capacity for the production of vaccines and biopharmaceuticals, with the goal of addressing the public health needs of Panama, Brazil, and, in particular, Central America and the Caribbean. This commitment aligns with the efforts led by Senacyt to create the Regional Center for Innovation in Vaccines and Biopharmaceuticals (CRIVB), a strategic initiative that seeks to position Panama as a regional benchmark in biopharmaceutical research, development, and production. Fiocruz, a leading institution in public health, biomedical research, and vaccine production in Brazil, will be a key partner in this joint effort.
